TCON TRACON Pharmaceuticals Inc.: שווי פעילות לרווח לפני ריבית, מסים ופחת

TRACON Pharmaceuticals (TCON) is currently winding down its business and liquidating assets due to the cessation of medical trials. The company previously ensured the strict transportation of biomaterials to protect patients within the scope of these studies. This price chart, which serves as confirmation of the market valuation where EV/EBITDA stands at , illustrates the position of the developer of targeted methods for combating rare types of sarcomas for oncology centers.

The EV/EBITDA ratio trajectory determines the market value of TRACON Pharmaceuticals (TCON), accounting for net debt relative to operating profit. This indicator measures the business value by considering the impact of borrowing costs and the tax burden on total capitalization. For a biopharmaceutical company investing in antibody development, this multiple serves as a marker of capital structure stability prior to the drug commercialization stage.